AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comSEP 242 min read$AMGN

Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks

Amgen (AMGN) rose 9.5% post-earnings, trading at $225.10. Myriad Genetics (MYGN) reported a 10.5% revenue decline, missing estimates, and fell 25.3% to $4.01. Novavax (NVAX) beat expectations with a 76.3% revenue drop but gained 36.7% to $10.53. Halozyme Therapeutics (HALO) grew revenue 47.7%, beating estimates, and rose 31.5% to $112.81.

Original reporting
finance.yahoo.com
Published Sep 24, 2026, 9:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 11:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$AMGNBullishLow
01

Why it matters

Recap of earnings with no new fundamental data; price moves reflect market digestion of prior reports.

02

Market read

Provides a quick snapshot of therapeutic sector performance; useful for traders monitoring short‑term momentum.

03

What to watch

Potential upcoming pipeline updates or regulatory news could shift sentiment beyond the earnings recap.

Relevance 4/10Novelty 2/10Timing: post‑earnings recap

Background

The article summarizes Q2 earnings outcomes for four therapeutic companies, noting stock price reactions since the results were released weeks earlier.

Company-level read

Ticker impact

$AMGNBullishMedium confidence
Context

Stock up 9.5% since reporting Q2 results, trading at $225.10.

Expected impact

Potential short‑term upside as momentum continues.

Evidence & confidence

Move reflects market digest of already‑released earnings; no new fundamental data.

$MYGNBearishMedium confidence
Context

Stock down 25.3% since Q2 results, trading at $4.01 after revenue miss and weak guidance.

Expected impact

Further downside possible if guidance remains below expectations.

Evidence & confidence

Recap of already‑published earnings; no fresh information.

$NVAXBullishMedium confidence
Context

Stock up 36.7% since reporting, trading at $10.53 after revenue beat.

Expected impact

Short‑term upside may persist pending further guidance.

Evidence & confidence

Move reflects market reaction to known earnings numbers.

$HALOBullishMedium confidence
Context

Stock up 31.5% since reporting, trading at $112.81 after revenue surge and guidance raise.

Expected impact

Momentum could continue in the near term.

Evidence & confidence

Recap of already‑released earnings; no new data.

Market effects

Sector

Therapeutics sector shows mixed reactions to Q2 earnings, highlighting divergence in growth trajectories.

Regional

U.S. biotech stocks experience varied price moves, influencing broader health‑care index performance.

Global

Limited; primarily affects U.S. listed biotech equities.

Counterpoint

What could challenge this read

Despite strong moves, the underlying earnings were already known; price action may be short‑lived.

Key entities

  • Company
    Amgen

    Biotech giant with 9.5% stock rise post‑Q2 earnings.

  • Company
    Myriad Genetics

    Genetic testing firm with 25.3% stock decline after earnings miss.

  • Company
    Novavax

    Vaccine maker up 36.7% after revenue beat.

  • Company
    Halozyme Therapeutics

    Drug delivery specialist up 31.5% after strong Q2.

Read at source← All news

Related articles

OCT 14
$AMGNHighAI 8/10

Wall Street Falls as Hot US Inflation Fuels Fed Rate Hike Bets

Wall Street indices fell Wednesday after hotter-than-expected US inflation data raised Fed rate hike bets. S&P 500, Nasdaq, and Dow Jones declined. CPI rose 0.6% month-over-month, with annual inflation at 3.7%. Tech shares dropped, while healthcare stocks gained. Treasury yields initially surged but later retreated. Corporate earnings from Bank of America, Morgan Stanley, and BlackRock influenced sentiment.

econotimes.com3 min
OCT 13
$AMGNMed

AMGN Maintained by Guggenheim -- Price Target Lowered to $378

Guggenheim maintained a Neutral rating on Amgen (AMGN) but lowered its price target from $388 to $378. Amgen's stock is currently trading at $417.57, which is 13.4% above its GF Value™ of $368.11, indicating overvaluation. The company has a GF Score™ of 85/100, showing strong financial health and profitability. Insider activity shows significant selling in the last three months.

gurufocus.com2 min
OCT 13
$HALOHigh

H.C. Wainwright reiterates Halozyme stock rating on FDA approval

H.C. Wainwright reiterated a Buy rating and $130 price target for Halozyme Therapeutics (HALO) after FDA approved Roche's cancer treatment using Halozyme's technology. HALO trades at $111.08, with 17% upside to the target. The approval offers a 12-month adjuvant royalty opportunity for Halozyme, though the addressable population is relatively small. Halozyme also won a patent case against Merck and completed a $1.5B convertible notes offering.

investing.com2 min
OCT 9
$MRNAHighAI 8/10

A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally - Moderna (NASDAQ:MRNA), BioNTec

A new NIH initiative to accelerate personalized cancer vaccine development has sparked a rally in biotech stocks. Moderna, Novavax, BioNTech, Pfizer, Merck, and Vaxcyte saw gains. The program, launching in December, focuses on pancreatic, liver, colorectal cancers, and childhood tumors. Moderna and Merck reported positive Phase 3 results for their mRNA cancer vaccine in August. BioNTech is advancing multiple cancer therapies.

benzinga.com2 min